165 related articles for article (PubMed ID: 38264853)
1. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Abou Chakra M; Packiam VT; Duquesne I; Peyromaure M; McElree IM; O'Donnell MA
Expert Opin Pharmacother; 2024 Feb; 25(2):203-214. PubMed ID: 38264853
[TBL] [Abstract][Full Text] [Related]
2. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
[TBL] [Abstract][Full Text] [Related]
3. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer.
McElree IM; Orzel J; Stubbee R; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Dec; 41(12):485.e1-485.e7. PubMed ID: 37442741
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
[TBL] [Abstract][Full Text] [Related]
5. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
6. Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer.
Abou Chakra M; McElree IM; Packiam VT; Mott SL; O'Donnell MA
Urol Oncol; 2024 Sep; 42(9):289.e13-289.e21. PubMed ID: 38796357
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Pareek T; Parmar K; Sharma AP; Kumar S
Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025
[TBL] [Abstract][Full Text] [Related]
8. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA
Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.
Abou Chakra M; Packiam VT; O'Donnell MA
Expert Opin Pharmacother; 2023; 24(18):2081-2091. PubMed ID: 37842956
[TBL] [Abstract][Full Text] [Related]
10. Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
Ben-David R; Tillu N; Alerasool P; Bieber C; Ranti D; Tolani S; Eisenhauer J; Chung R; Lavallée E; Waingankar N; Attalla K; Wiklund P; Mehrazin R; Anderson CB; Sfakianos JP
World J Urol; 2024 May; 42(1):315. PubMed ID: 38734774
[TBL] [Abstract][Full Text] [Related]
11. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
12. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
13. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
Tan WS; McElree IM; Davaro F; Steinberg RL; Bree K; Navai N; Dinney CP; O'Donnell MA; Li R; Kamat AM; Packiam VT
Eur Urol Oncol; 2023 Oct; 6(5):531-534. PubMed ID: 37468392
[TBL] [Abstract][Full Text] [Related]
14. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
Kawada T; Yanagisawa T; Araki M; Pradere B; Shariat SF
Curr Opin Urol; 2023 May; 33(3):211-218. PubMed ID: 36482766
[TBL] [Abstract][Full Text] [Related]
15. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
16. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
Moussa M; Abou Chakra M; Shore ND; Papatsoris A; Farahat Y; O'Donnell MA
Arch Ital Urol Androl; 2024 Mar; 96(1):12244. PubMed ID: 38502039
[TBL] [Abstract][Full Text] [Related]
17. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
Balasubramanian A; Gunjur A; Weickhardt A; Papa N; Bolton D; Lawrentschuk N; Perera M
World J Urol; 2022 May; 40(5):1111-1124. PubMed ID: 35083522
[TBL] [Abstract][Full Text] [Related]
19. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
Bukavina L; Bell S; Packiam VT; Smaldone M; Abbosh P; Uzzo R; Kutikov A; Correa AF; Magee DE
Urol Oncol; 2023 Sep; 41(9):391.e1-391.e4. PubMed ID: 37127478
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F
Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]